Tomoaki Ichikawa, MD ; Hironobu Sou, MD ; Tsutomu Araki, MD ; Ali S. Arbab, MD ; Takeharu Yoshikawa, MD ; Keiichi Ishigame, MD ; Hiroki Haradome, MD ; Junichi Hachiya, MD
1 From the Department of Radiology, Yamanashi Medical University, 1110 Shimokato, Tamaho, Nakakoma, Yamanashi 409-3815, Japan (T.I., H.S., T.A., A.S.A., T.Y., K.I.); and Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan (H.H., J.H.). Received June 30, 2000; revision requested August 8; final revision received and accepted April 17, 2001.
PURPOSE: To define the duct-penetrating sign at magnetic resonance (MR) cholangiopancreatography (MRCP) and to assess the usefulness of this sign for distinguishing an inflammatory pancreatic mass (IPM) from a conventional pancreatic carcinoma (CPC) compared with arterial phase computed tomography (hereafter, CT) and arterial phase MR imaging (hereafter, MR imaging).